Table 24Cancer Incidence and Mortality Among Selenium Studies

OutcomeStudyComparisonMean followup (y)Intervention, # of subjects with events (%)Comparator, # of subjects with events (%)RR or HR95% CIP-value
Any cancer incidenceNPC89,90,92Selenium vs. placebo677/653 (11.8)119/659 (18.1)0.630.47 to 0.850.001
7.4105/621 (16.9)137/629 (21.8)0.750.58 to 0.980.03
SELECT82Selenium vs. placebo5837/8,752 (9.6)824/8,696 (9.5)1.01*0.89 to 1.15NR
121,132/8,752 (12.9)1,108/8,696 (12.7)1.02*0.92 to 1.140.59
Selenium + vitamin E vs. placebo5846/8,703 (9.7)824/8,696 (9.5)1.02*0.90 to 1.16NR
121,149/8,703 (13.2)1,108/8,696 (12.7)1.02*0.92 to 1.140.60
Prostate cancer incidenceNPC89,90,92,93,95Selenium vs. placebo613/479 (2.7)35/495 (7.1)0.370.18 to 0.710.002
7.422/457 (4.8)42/470 (8.9)0.510.29 to 0.880.009
SELECT82Selenium vs. placebo5432/8,752 (4.9)416/8,696 (4.8)1.04*0.90 to 1.180.62
12575/8,752 (6.6)529/8,696 (6.1)1.09*0.93 to 1.270.18
Selenium + vitamin E vs. placebo5437/8,703 (5)416/8,696 (4.8)1.05*0.91 to 1.200.52
12555/8,703 (6.4)529/8,696 (6.1)1.05*0.89 to 1.220.46
Lung cancer incidenceNPC89,90,92,94Selenium vs. placebo617/653 (2.6)31/659 (4.7)0.540.30 to 0.980.04
7.425/621 (4)35/629 (5.6)0.700.40 to 1.210.18
SELECT82Selenium vs. placebo575/8,752 (0.9)67/8,696 (0.8)1.12*0.73 to 1.72NR
1294/8,752 (1.1)92/8,696 (1.1)1.02*0.70 to 1.500.89
Selenium + vitamin E vs. placebo578/8,703 (0.9)67/8,696 (0.8)1.16*0.76 to 1.78NR
12104/8,703 (1.2)92/8,696 (1.1)1.11*0.76 to 1.620.48
Colorectal cancer incidenceNPC89,90,92Selenium vs. placebo6.38/653 (1.2)19/659 (2.9)0.420.18 to 0.950.03
7.49/621 (1.4)19/629 (3)0.460.19 to 1.080.055
SELECT82Selenium vs. placebo563/8,752 (0.7)60/8,696 (0.7)1.05*0.66 to 1.67NR
1274/8,752 (0.8)75/8,696 (0.9)0.96*0.63 to 1.460.79
Selenium + vitamin E vs. placebo577/8,703 (0.9)60/8,696 (0.7)1.28*0.82 to 2.00NR
1293/8,703 (1.1)75/8,696 (0.9)1.21*0.81 to 1.810.22
Breast cancer incidenceNPC89,90Selenium vs. placebo6.39/653 (1.4)3/659 (0.5)2.880.72 to 16.50.09
7.411/621 (1.8)6/629 (1)1.820.62 to 6.010.24
Any cancer deathNPC89,90,92Selenium vs. placebo6.329/653 (4.4)57/659 (8.6)0.500.31 to 0.800.002
7.440/621 (6.4)66/629 (10.5)0.590.39 to 0.890.008
SELECT82Selenium vs. placebo5128/8,752 (1.5)125/8,696 (1.4)1.02*0.74 to 1.41NR
Selenium + vitamin E vs. placebo5117/8,703 (1.3)125/8,696 (1.4)0.93*0.67 to 1.30NR
Lung cancer deathNPC89,92Selenium vs. placebo612/653 (1.8)25/659 (3.8)0.470.22 to 0.980.03
SELECT82Selenium vs. placebo545/8,752 (6.9)41/8,696 (6.2)1.10*0.63 to 1.91NR
Selenium + vitamin E vs. placebo539/8,703 (0.4)41/8,696 (0.5)0.95*0.53 to 1.69NR
Prostate cancer deathSELECT82Selenium vs. placebo51/8,752 (0)0/8,696 (0)NANANA
Selenium + vitamin E vs. placebo50/8,703 (0)0/8,696 (0)NANANA
Colorectal cancer deathSELECT82Selenium vs. placebo510/8,752 (0.1)10/8,696 (0.1)1.00*0.32 to 3.16NR
Selenium + vitamin E vs. placebo515/8,703 (0.2)10/8,696 (0.1)1.49*0.52 to 4.28NR
*

HR; analyses did not incorporate adjustments for baseline covariates.

99% CI reported.

Unadjusted.

Abbreviations: CI = confidence interval; HR = hazard ratio; NA = not applicable; NPC = Nutritional Prevention of Cancer; NR = not reported; RR = relative risk; SELECT = Selenium and Vitamin E Cancer Prevention Trial; y = years.

From: 3, Results

Cover of Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer
Vitamin, Mineral, and Multivitamin Supplements for the Primary Prevention of Cardiovascular Disease and Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 108.
Fortmann SP, Burda BU, Senger CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.